Latest XTLB reports update at 2024-04-27: 2022 ∙ 2021 ∙ 2020

XTL Biopharmaceuticals Ltd. XTLB

$ 2.49 0.81%

XTL Biopharmaceuticals Ltd. Financial Statements 2011-2024 | XTLB

Annual Financial Statements XTL Biopharmaceuticals Ltd.

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	-	1.27 B	16.6 M	6.89 M	11.8 M	8.42 M	8.22 M	17.4 M	23.1 M	41.3 M	65.3 M	37.7 M
Shares	-	532 M	5.14 M	5.14 M	5.14 M	4.7 M	2.74 M	2.64 M	2.31 M	2.24 M	2.18 M	2.04 M
Historical Prices	0.83	2.38	3.22	1.34	2.3	1.79	2	6.8	11.8	20.2	34.5	21.5
Net Income	-	435 K	-782 K	-1.35 M	2.99 M	-781 K	-2.54 M	-4.31 M	-2.53 M	-2.48 M	-1.39 M	-1.21 M
Revenue	-	-	-	-	-	-	-	-	-	2.37 M	938 K	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	1.63 M	558 K	-
Operating Income	-	-1.03 M	-948 K	-842 K	-793 K	-1.25 M	-2.56 M	-3.61 M	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-1.03 M	-948 K	-842 K	-793 K	-1.25 M	-1.71 M	-1.99 M	-2.01 M	-2.2 M	-2.34 M	-1.15 M
Operating Expenses	-	-	-	842 K	793 K	1.25 M	1.71 M	2 M	2.02 M	3.85 M	2.91 M	1.25 M
General and Administrative Expenses	-	1 M	910 K	807 K	755 K	1.19 M	1.26 M	1.41 M	1.72 M	1.98 M	2.77 M	1.08 M

All numbers in USD currency

Quarterly Income Statement XTL Biopharmaceuticals Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	-	-	-	528 M	-	-	-	514 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-1.15 M	-	-	-	-1.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-303 K	-	-	-	-217 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-303 K	-	-	-	-217 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	-	-	-	-	297 K	-	-	-	206 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency